Abstract
Twelve premenopausal patients with advanced breast cancer were randomised to receive 3.75 or 7.5 mg of a slow release formulation of the luteinising hormone releasing hormone agonist leuprorelin once every 4 weeks. All patients were oestrogen receptor positive or unknown. Serum levels of gonadotrophins and oestrogens were suppressed markedly by both doses. All oestrogen values during treatment were within the postmenopausal range except for a single oestradiol level (274 pmol l-1) in one patient on the lower dose. There was no other indication that this lower dose was less effective as an oestrogen suppressant. There were two objective responders to the 3.75 mg dose and three to the 7.5 mg dose. Toxicity was confined almost entirely to hot flushes which occurred in 11/12 patients. We conclude that the slow release formulation of leuprorelin is effective in breast cancer treatment and that there is no major detriment to the use of the 3.75 rather than 7.5 mg dose.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dowsett, M., Mehta, A., Mansi, J. et al. A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients. Br J Cancer 62, 834–837 (1990). https://doi.org/10.1038/bjc.1990.388
Issue Date:
DOI: https://doi.org/10.1038/bjc.1990.388
This article is cited by
-
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5Â years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
Breast Cancer (2021)
-
A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5Â years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
Breast Cancer (2016)
-
The role of ovarian ablation in the adjuvant therapy of breast cancer
Current Oncology Reports (2008)